CORRECTION article
Front. Endocrinol.
Sec. Cardiovascular Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1663787
A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
Provisionally accepted
- Grupo interinstitucional de medicina interna (GIMI 1). Universidad libre. Seccional Cali, Cali, Colombia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
.
Keywords: cardiovascular outcomes, SGLT2 inhibitors, GLP-1 agonists, combination therapy, heart failure, Renal outcomes
Received: 10 Jul 2025; Accepted: 28 Jul 2025.
Copyright: © 2025 Vernaza Trujillo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: David Alexander Vernaza Trujillo, Grupo interinstitucional de medicina interna (GIMI 1). Universidad libre. Seccional Cali, Cali, Colombia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.